Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Soelberg Sorensen

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
The Lancet. Neurology|December 29, 2004
Multiple sclerosis: pathophysiology revisitedPer Soelberg Sorensen
Current Opinion in Neurology|April 25, 2014
New management algorithms in multiple sclerosisPer Soelberg Sorensen
CNS Drugs|July 25, 2022
Correction to: Antidrug Antibodies Against Biological Treatments for Multiple SclerosisPer Soelberg Sorensen
Journal of the Neurological Sciences|March 17, 2007
The gap between effect of drugs and effectiveness of treatmentsPer Soelberg Sorensen
The Lancet. Neurology|April 2, 2014
Effects of fingolimod in relapsing-remitting multiple sclerosisPer Soelberg Sorensen
Journal of the Neurological Sciences|February 1, 2003
The role of intravenous immunoglobulin in the treatment of multiple sclerosisPer Soelberg Sorensen
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2016
Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - NOPer Soelberg Sorensen
Neuro-Degenerative Diseases|December 14, 2007
Intravenous polyclonal human immunoglobulins in multiple sclerosisPer Soelberg Sorensen
Neurology|October 31, 2008
Can we spot the IFNbeta nonresponders?Per Soelberg Sorensen
Therapeutic Advances in Neurological Disorders|December 25, 2010
Neutralizing antibodies against interferon-BetaPer Soelberg Sorensen
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
The Lancet. Neurology|December 29, 2004
Multiple sclerosis: pathophysiology revisitedPer Soelberg Sorensen
Current Opinion in Neurology|April 25, 2014
New management algorithms in multiple sclerosisPer Soelberg Sorensen
CNS Drugs|July 25, 2022
Correction to: Antidrug Antibodies Against Biological Treatments for Multiple SclerosisPer Soelberg Sorensen
Journal of the Neurological Sciences|March 17, 2007
The gap between effect of drugs and effectiveness of treatmentsPer Soelberg Sorensen
The Lancet. Neurology|April 2, 2014
Effects of fingolimod in relapsing-remitting multiple sclerosisPer Soelberg Sorensen
Journal of the Neurological Sciences|February 1, 2003
The role of intravenous immunoglobulin in the treatment of multiple sclerosisPer Soelberg Sorensen
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2016
Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - NOPer Soelberg Sorensen
Neuro-Degenerative Diseases|December 14, 2007
Intravenous polyclonal human immunoglobulins in multiple sclerosisPer Soelberg Sorensen
Neurology|October 31, 2008
Can we spot the IFNbeta nonresponders?Per Soelberg Sorensen
Therapeutic Advances in Neurological Disorders|December 25, 2010
Neutralizing antibodies against interferon-BetaPer Soelberg Sorensen
Pageof 8